Status In progress
Process STA
ID number 1327

Provisional Schedule

Final appraisal determination 17 May 2018 - 01 June 2018
Expected publication 20 June 2018

Project Team

Project lead Joanne Ekeledo

Email enquiries


Companies sponsors Roche
Others Department of Health
  NHS England
  Welsh Government
Patient carer groups Action Bladder Cancer
  Fight Bladder Cancer
Professional groups British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  Urology Foundation


Comparator companies Accord Healthcare (carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Actavis UK (docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Dr Reddy's Laboratories (docetaxel) (CAU not returned, not participating)
  Eli Lilly (gemcitabine) (CAU not returned, not participating)
  Hospira (carboplatin, docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Medac (docetaxel, gemcitabine, paclitaxel) (CAU not returned, not participating)
  Sanofi (docetaxel) (CAU not returned, not participating)
  Seacross Pharmaceuticals (docetaxel) (CAU not returned, not participating)
  Sun Pharmaceuticals UK Ltd (carboplatin, gemcitabine) (CAU not returned, not participating)
  Peckforton Pharmaceuticals (paclitaxel) (CAU not returned, not participating)
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
11 April 2018 Committee meeting: 4
13 March 2018 A final appraisal determination (FAD) for the above appraisal was scheduled to be released for appeal this week. The company that markets atezolizumab, Roche Products, has requested that NICE consider a new value proposition for this population. NICE has agreed to this and therefore the FAD release has been suspended. A further update on the appraisal and associated timelines will follow in due course.
22 December 2017 - 17 January 2018 Appraisal consultation
23 November 2017 Committee meeting: 3
23 October 2017 This technology appraisal was originally included in scope for ID939. More evidence for this group became available after the original committee discussion of ID939, so a separate document (and subsequent guidance) will be developed for this population.
26 September 2017 In progress, In progress
30 August 2017 Committee meeting: 2
02 August 2017 - 23 August 2017 Appraisal consultation: 1
26 April 2017 Committee meeting: 1
09 November 2016 Invitation to participate
08 June 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance